Cartherics to test new product for ovarian cancer in clinical trials
A much-anticipated new treatment for ovarian cancer discovered in Melbourne is also being explored for other conditions ...
businessnewsaustralia6d
Cartherics raises $15m to advance its bid to rearm immune systems to fight ovarian cancer
Melbourne-based biotechnology company Cartherics has raised $15 million to help advance its mission to rearm the body's ...
Startup Daily5d
Biotech startup Cartherics doses up on $15 million raise for cancer treatment trials
The latest funding will support the first clinical trial for CTH-401, the startup’s lead cell therapy product, to treat ovarian cancer.
Eight ANZ startups that raised at least $66.3 million this week
Australian and Kiwi startups in fields as diverse as cell therapy, wastewater treatment, and local government software raised ...
BioWorld4d
Cartherics' AU$15M series B advances CTH-401 for ovarian cancer
Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor ...
Cartherics Raises Over $15 Million In Oversubscribed Private Financing Round To Advance Cell Therapy Programs
Melbourne, Australia, 1 October 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is ...
precisionmedicineonline4d
Cartherics Raises A$15M, Plans to Evaluate NK-Based Cell Therapy in Ovarian Cancer
With help from the oversubscribed financing round, the Australian firm is eyeing early 2025 for a Phase I clinical trial of its TAG-72-targeting cell therapy.